A citation-based method for searching scientific literature

Laurent Azoulay, Kristian B Filion, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Madeleine Durand, David N Juurlink, Laura E Targownik, Tanvir C Turin, J Michael Paterson, Pierre Ernst. BMJ 2016
Times Cited: 61







List of co-cited articles
454 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
49

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
36

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
34

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
34

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Amy G Egan, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh. N Engl J Med 2014
316
32

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
21


Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
768
21

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gale. Diabetes Care 2013
192
19

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Laurent Azoulay, Kristian B Filion, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Madeleine Durand, Nianping Hu, David N Juurlink, J Michael Paterson,[...]. JAMA Intern Med 2016
53
20

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
18

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
M Gokhale, J B Buse, C L Gray, V Pate, M A Marquis, T Stürmer. Diabetes Obes Metab 2014
52
19

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Ling Li, Jiantong Shen, Malgorzata M Bala, Jason W Busse, Shanil Ebrahim, Per Olav Vandvik, Lorena P Rios, German Malaga, Evelyn Wong, Zahra Sohani,[...]. BMJ 2014
140
16

Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
L M Knapen, J van Dalem, Y C Keulemans, N P van Erp, M T Bazelier, M L De Bruin, H G M Leufkens, S Croes, C Neef, F de Vries,[...]. Diabetes Obes Metab 2016
21
47

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
16

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
14

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
14

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Lotte Bjerre Knudsen, Lars Wichmann Madsen, Søren Andersen, Kasper Almholt, Anne S de Boer, Daniel J Drucker, Carsten Gotfredsen, Frederikke Lihme Egerod, Anne Charlotte Hegelund, Helene Jacobsen,[...]. Endocrinology 2010
338
14

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
13

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
344
13

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
255
13

Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci. Diabetes Obes Metab 2017
71
13


Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
John A Romley, Dana P Goldman, Matthew Solomon, Daniel McFadden, Anne L Peters. Diabetes Technol Ther 2012
62
11

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
11


A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Carlos Alves, Francisco Batel-Marques, Ana F Macedo. Diabetes Res Clin Pract 2012
102
11


GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
381
11

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
11

Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
Heidi Storgaard, Frederik Cold, Lise L Gluud, Tina Vilsbøll, Filip K Knop. Diabetes Obes Metab 2017
51
13


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
9

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
9


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
9


3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
241
9

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
473
8

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Itamar Raz, Deepak L Bhatt, Boaz Hirshberg, Ofri Mosenzon, Benjamin M Scirica, Amarachi Umez-Eronini, KyungAh Im, Christina Stahre, Alona Buskila, Nayyar Iqbal,[...]. Diabetes Care 2014
44
11




Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
472
8

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
Kristian B Filion, Laurent Azoulay, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Nianping Hu, J Michael Paterson, Laura Targownik, Tanvir C Turin,[...]. N Engl J Med 2016
146
8


Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Aleksey V Matveyenko, Sarah Dry, Heather I Cox, Artemis Moshtaghian, Tatyana Gurlo, Ryan Galasso, Alexandra E Butler, Peter C Butler. Diabetes 2009
183
8

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
705
8


Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
864
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.